Literature DB >> 23429097

Advances in nanotechnology for diagnosis and treatment of tuberculosis.

Shelza Banyal1, Parth Malik, Hardeep S Tuli, Tapan K Mukherjee.   

Abstract

PURPOSE OF REVIEW: Tuberculosis (TB) has been a most turbulent problem prevailing for the last several decades. The emergence of multidrug-resistant strains and the dearth of anti-TB drugs are threatening the future containment of TB. Nanotechnology presents an exciting opportunity for proper identification of mycobacterial strains and to improve the potential of drugs for the treatment of TB. RECENT
FINDINGS: Nanoscience has provided humankind with several unique and comparatively more effective drug delivery carriers, encompassing liposomal-mediated drug delivery, solid lipid nanoparticles, polymeric nanoparticles, dendrimers, nanoemulsions, nanosuspensions and other nanosystems exploiting the extraordinary properties of matter at the nanoscale. Nanoparticle-based assays have shown significant improvements in diagnosis, treatment and prevention of TB. Nanoparticles as drug carriers enable higher stability and carrier capacity along with immense improvement of drug bioavailability which further leads to reduction in dosage frequency.
SUMMARY: This review covers the prospect of using nanotechnology for the detection of mycobacterial strains and nanotechnology-based drug delivery systems for effective eradication of mycobacterial infections.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23429097     DOI: 10.1097/MCP.0b013e32835eff08

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  3 in total

Review 1.  Cure of tuberculosis using nanotechnology: An overview.

Authors:  Rout George Kerry; Sushanto Gouda; Bikram Sil; Gitishree Das; Han-Seung Shin; Gajanan Ghodake; Jayanta Kumar Patra
Journal:  J Microbiol       Date:  2018-05-02       Impact factor: 3.422

2.  Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes.

Authors:  Benson J Edagwa; Dongwei Guo; Pavan Puligujja; Han Chen; JoEllyn McMillan; Xinming Liu; Howard E Gendelman; Prabagaran Narayanasamy
Journal:  FASEB J       Date:  2014-08-13       Impact factor: 5.191

3.  Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study.

Authors:  Ning-Kui Niu; Juan-Juan Yin; Yin-Xue Yang; Zi-Li Wang; Zhi-Wei Zhou; Zhi-Xu He; Xiao-Wu Chen; Xueji Zhang; Wei Duan; Tianxin Yang; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-08-07       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.